RxDoctor Payments Data

Noel Vargas-Perez, MD

Sleep Medicine · Aguadilla, PRNPI 1154655702

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $914 of the $1,232 with a category attached, or 74.2%. 10 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 26.8% of the total. 2025 is the largest year on record at $419, 3.2 times the $133 reported in 2019.

$1,232in general payments, 2019–2025

Across 33 payments — averaging $37.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$330
  • Harmony Biosciences LLC$323
  • Novartis$190
  • Biogen$121
  • Lilly USA, LLC$90
  • Biohaven Pharmaceutical Holding Company Ltd.$50
  • plus $129 from 4 others

What the payments were for

  • Food & beverage$91474%
  • Education$31726%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few sleep medicine providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$32,057
Medicare patients
41
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm50$38,152
NeuproRotigotine14$11,973
ReyvowLasmiditan Succinate11$8,301
Rivastigmine59$7,265
Memantine Hcl490$5,112
Donepezil Hcl566$3,008
Carbidopa-LevodopaCarbidopa/Levodopa67$2,470
RivastigmineRivastigmine Tartrate63$1,697
Levetiracetam77$1,584
Gabapentin161$1,339
Doxepin Hcl100$1,201
Galantamine Hbr30$1,119
Selegiline Hcl17$1,090
Fluticasone Propionate78$1,060
Divalproex Sodium31$984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCReyvow$90$8,30111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few sleep medicine providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other sleep medicine in Aguadilla

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →